D8-MMAE, inhibitor

D8-MMAE

Cat. Num. AAA5752979

• Purity: 98.00%
• Synonyms: D8-MMAE; D8-Monomethyl auristatin E; inhibitor

• Purity/Purification: 98.00%
• Form/Format: Solid. Powder

• Solubility: DMSO: 100mg/mL (137.74mM) Need ultrasonic; (<1mg/ml refers to the product slightly soluble or insoluble)
• Formula: C39H59D8N5O7
• SMILES: CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@@](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])([2H])NC([C@H](C(C)C)NC)=O)=O)C
• CAS Number: 2070009-72-0
• Target & IC50: Others
• In Vitro: In tumor xenograft models, themMAE concentration in the tumor is always correlated with the degree of tumor growth inhibition. IHC analysis showed that tumors that were not combined with control treatment, consisted of CD30 + and CD30 cells, presumably because they did not kill CD30 + or CD30- Karpas 299 cells. Only CD30-cells were found in tumors treated with cAC10-vcMMAF, indicating that cAC10-vcMMAF eliminated most CD30 + cells. Interestingly, at the end of the study, two tumors recurring from the treatment of cAC10-vcMMAE were also found to be CD30-, indicating that in the remaining two tumors, a small portion of CD30-cells may have escaped bystanders Kill.
• Preparation and Storage: Store at -20 degree C for 3 years powder; -80 degree C for 2 years in solvent

Structure

Related Product Information for D8-MMAE, inhibitor

D8-MMAE (D8-Monomethyl auristatin E) is an effective mitotic inhibitor and tubulin inhibitor, deuterated MMAE.

References

Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9.
Li F, et al. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models. Cancer Res. 2016 May 1;76(9):2710-9.